Our technology platform utilizes fluid dynamics ― specifically Taylor-Couette-Poiseuille (TCP) flow ― to generate therapeutics from biologically active gases to restore cellular homeostasis. The goal is to produce drugs like RNS60, which have broad benefits across multiple cell types versus the single receptor-targeted approach that has not proven to be successful in areas like ischemic stroke.

Key biological mechanisms

Our lead candidate, RNS60, activates the Akt pathway, a master regulator of cell survival. This activation leads to several critical outcomes:

1. Preserving structure and function of mitochondria, effectively "re-powering" the cell.
2. Enhanced neuronal survival under various stresses through activation of the Akt-mediated antiapoptotic pathway.
3. Promotion of an anti-inflammatory environment that supports neuroprotection through modulation of the activity of immune cells (like microglia, astroglia and T cells).